Canadian Journal of Neurological Sciences: Volume 51 - Issue 6

A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy
Rayan Yanes, Joel Neves Briard, Tang-Duc Jeremy Nguyen, Maya Sultanem, Dang Khoa Nguyen, Steve Gibbs, Kristin Ikeda, Jeffrey Jirsch, Colin Josephson, Lysa Boisse Lomax, Véronique Cloutier, Mark Keezer
Published online by Cambridge University Press:

27 December 2023, pp. 860-864
- Article
- - You have access
- PDF
- HTML
- Export citation
We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.

Canadian Journal of Neurological Sciences